98069-56-8

Usage

Uses

Used in Pharmaceutical Industry:
Cyclobutanecarboxylic acid, hydrazide (6CI, 9CI) is used as a synthetic intermediate for the development of various pharmaceutical products. Its unique chemical structure allows it to be a key component in the synthesis of new drugs, contributing to the advancement of medical treatments.
Used in Agrochemical Industry:
In the agrochemical industry, Cyclobutanecarboxylic acid, hydrazide (6CI, 9CI) is utilized as a building block for the creation of new agrochemicals. Its reactivity and versatility make it a valuable asset in the development of innovative agricultural chemicals, enhancing crop protection and productivity.
Used in Research and Development:
Cyclobutanecarboxylic acid, hydrazide (6CI, 9CI) is employed as a research compound in the exploration of new drug and agrochemical candidates. Its role as a reactive intermediate facilitates the discovery and optimization of novel organic compounds with potential applications in various industries.

InChI:InChI=1/C5H10N2O/c6-7-5(8)4-2-1-3-4/h4H,1-3,6H2,(H,7,8)

Upstream product

• 14924-53-9 ethyl cyclobutylcarboxylate 
• 765-85-5 methyl cyclobutanecarboxylate 
• 3721-95-7 Cyclobutanecarboxylic acid 

Downstream Products

• 1477523-87-7 2-(4-(4′-(5-cyclobutyl-1,3,4-oxadiazol-2-ylamino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetic acid 
• 1477524-28-9 methyl 2-(4-(4'-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)-[1,1'-biphenyl]-4-yl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate 
• 1477524-12-1 methyl 2-(4-(4-(5-((5-cyclobutyl-1,3,4-oxadiazol-2-yl)amino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate 
• 1477523-85-5 2-(4-(4-(6-((5-cyclobutyl-1,3,4-thiadiazol-2-yl)amino)pyridin-3-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetic acid 
• 1477523-83-3 2-(4-(4-(5-((5-cyclobutyl-1,3,4-thiadiazol-2-yl)amino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetic acid 

Relevant academic research and scientific papers

Design and synthesis in silico drug-like prediction and pharmacological evaluation of cyclopolymethylenic homologous of lassbio-1514

Acylhydrazones are still an important framework to the design of new bioactive com-pounds. As treatment of chronic pain represents a clinical challenge, we decided to modify the structure of LASSBio-1514 (1), previously described as anti-inflammatory and analgesic proto-type. Applying the homologation as a strategy for molecular modification, we designed a series of cyclopentyl-(2a–e), cyclobutyl-(3a–e), and cyclopropylacylhydrazones (4a–e) that were synthetized and evaluated in murine models of inflammation and pain. A comparison of their in silico physico-chemical and drug-like profile was conducted, as well as their anti-inflammatory and analgesic effect. Compounds 4a (LASSBio-1755) and 4e (LASSBio-1757) displayed excellent in silico drug-like profiles and were identified as new analgesic lead-candidates in acute and chronic model of pain, through oral administration.

SSAO INHIBITOR

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

Synthesis of 3-hydroxyindanones via potassium salt of amino acid catalyzed regioselective intramolecular aldolization of ortho-diacylbenzenes

First organocatalytic intramolecular aldolization of ortho-diacylbenzenes to construct highly functionalized 3-hydroxyindanones is described. In this transformation a high trans-selectivity is achieved by the use of metal salt of amino acid. This method allows an easy access to the strained spirocyclic 3-hydroxyindanones related to a number of natural product frameworks. Synthesis of a new class of indole skeleton substituted by 3-hydroxyindanones added an extra essence to this new protocol.